These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27897246)

  • 1. Rapid control of pandemic H1N1 influenza by targeting NKT-cells.
    Artiaga BL; Yang G; Hutchinson TE; Loeb JC; Richt JA; Lednicky JA; Salek-Ardakani S; Driver JP
    Sci Rep; 2016 Nov; 6():37999. PubMed ID: 27897246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant effects of invariant NKT cell ligand potentiates the innate and adaptive immunity to an inactivated H1N1 swine influenza virus vaccine in pigs.
    Dwivedi V; Manickam C; Dhakal S; Binjawadagi B; Ouyang K; Hiremath J; Khatri M; Hague JG; Lee CW; Renukaradhya GJ
    Vet Microbiol; 2016 Apr; 186():157-63. PubMed ID: 27016770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α-Galactosylceramide protects swine against influenza infection when administered as a vaccine adjuvant.
    Artiaga BL; Yang G; Hackmann TJ; Liu Q; Richt JA; Salek-Ardakani S; Castleman WL; Lednicky JA; Driver JP
    Sci Rep; 2016 Mar; 6():23593. PubMed ID: 27004737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exogenous Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Reduces Pneumococcal Outgrowth and Dissemination Postinfluenza.
    Barthelemy A; Ivanov S; Hassane M; Fontaine J; Heurtault B; Frisch B; Faveeuw C; Paget C; Trottein F
    mBio; 2016 Nov; 7(6):. PubMed ID: 27803187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses.
    Kamijuku H; Nagata Y; Jiang X; Ichinohe T; Tashiro T; Mori K; Taniguchi M; Hase K; Ohno H; Shimaoka T; Yonehara S; Odagiri T; Tashiro M; Sata T; Hasegawa H; Seino KI
    Mucosal Immunol; 2008 May; 1(3):208-18. PubMed ID: 19079180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unaltered influenza disease outcomes in swine prophylactically treated with α-galactosylceramide.
    Gu W; Madrid DMD; Yang G; Artiaga BL; Loeb JC; Castleman WL; Richt JA; Lednicky JA; Driver JP
    Dev Comp Immunol; 2021 Jan; 114():103843. PubMed ID: 32871161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vivo stimulation of macaque natural killer T cells with α-galactosylceramide.
    Fernandez CS; Jegaskanda S; Godfrey DI; Kent SJ
    Clin Exp Immunol; 2013 Sep; 173(3):480-92. PubMed ID: 23656283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.
    Ko SY; Ko HJ; Chang WS; Park SH; Kweon MN; Kang CY
    J Immunol; 2005 Sep; 175(5):3309-17. PubMed ID: 16116223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal but not intravenous delivery of the adjuvant α-galactosylceramide permits repeated stimulation of natural killer T cells in the lung.
    Courtney AN; Thapa P; Singh S; Wishahy AM; Zhou D; Sastry J
    Eur J Immunol; 2011 Nov; 41(11):3312-22. PubMed ID: 21818755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasally administered Endocine formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets.
    Maltais AK; Stittelaar KJ; Veldhuis Kroeze EJ; van Amerongen G; Dijkshoorn ML; Krestin GP; Hinkula J; Arwidsson H; Lindberg A; Osterhaus AD
    Vaccine; 2014 May; 32(26):3307-15. PubMed ID: 24690149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmenting Influenza-Specific T Cell Memory Generation with a Natural Killer T Cell-Dependent Glycolipid-Peptide Vaccine.
    Anderson RJ; Li J; Kedzierski L; Compton BJ; Hayman CM; Osmond TL; Tang CW; Farrand KJ; Koay HF; Almeida CFDSSE; Holz LR; Williams GM; Brimble MA; Wang Z; Koutsakos M; Kedzierska K; Godfrey DI; Hermans IF; Turner SJ; Painter GF
    ACS Chem Biol; 2017 Nov; 12(11):2898-2905. PubMed ID: 29043774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.
    Lee YS; Lee KA; Lee JY; Kang MH; Song YC; Baek DJ; Kim S; Kang CY
    Vaccine; 2011 Jan; 29(3):417-25. PubMed ID: 21087689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1).
    Matassov D; Cupo A; Galarza JM
    Viral Immunol; 2007 Sep; 20(3):441-52. PubMed ID: 17931114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral potential of exogenous human omega interferon to inhibit pandemic 2009 A (H1N1) influenza virus.
    Xu C; Song X; Fu L; Dong D; Wu S; Li G; Yi S; Yu T; Yu R; Hou L; Chen W
    Viral Immunol; 2011 Oct; 24(5):369-74. PubMed ID: 22004136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of oseltamivir and α-galactosylceramide for reducing disease and transmission in pigs infected with 2009 H1N1 pandemic influenza virus.
    Madrid DMC; Gu W; Artiaga BL; Yang G; Loeb J; Hawkins IK; Castleman WL; Lednicky JA; Richt JA; Driver JP
    Front Vet Sci; 2022; 9():999507. PubMed ID: 36337191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection of pigs against pandemic swine origin H1N1 influenza A virus infection by hemagglutinin- or neuraminidase-expressing attenuated pseudorabies virus recombinants.
    Klingbeil K; Lange E; Blohm U; Teifke JP; Mettenleiter TC; Fuchs W
    Virus Res; 2015 Mar; 199():20-30. PubMed ID: 25599604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
    Baranovich T; Bahl J; Marathe BM; Culhane M; Stigger-Rosser E; Darnell D; Kaplan BS; Lowe JF; Webby RJ; Govorkova EA
    Antiviral Res; 2015 May; 117():10-9. PubMed ID: 25701593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuraminidase Activity and Resistance of 2009 Pandemic H1N1 Influenza Virus to Antiviral Activity in Bronchoalveolar Fluid.
    Ruangrung K; Suptawiwat O; Maneechotesuwan K; Boonarkart C; Chakritbudsabong W; Assawabhumi J; Bhattarakosol P; Uiprasertkul M; Puthavathana P; Wiriyarat W; Jongkaewwattana A; Auewarakul P
    J Virol; 2016 May; 90(9):4637-4646. PubMed ID: 26912622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system.
    Youn HJ; Ko SY; Lee KA; Ko HJ; Lee YS; Fujihashi K; Boyaka PN; Kim SH; Horimoto T; Kweon MN; Kang CY
    Vaccine; 2007 Jul; 25(28):5189-98. PubMed ID: 17548137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.